Novo Nordisk (NVO) Stock Tumbles 9% as ZEUS Trial Falls Short of Cardiovascular Goals

Novo Nordisk (NVO) stock dropped 9% after its ZEUS cardiovascular trial failed to meet its primary endpoint, raising questions about ziltivekimab's future.

The post Novo Nordisk (NVO) Stock Tumbles 9% as ZEUS Trial Falls Short of Cardiovascular Goals appeared first on Blockonomi.